Cell line · CVCL_0497
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia-driven transcriptional activation of MIR100HG by HIF-1α contributes to adaptive gene regulation in hepatocellular carcinoma. | Funct Integr Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression. | JHEP Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma. | Cell Mol Gastroenterol Hepatol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Viscosity regulates cell spreading and cell-extracellular matrix interactions. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma. | Cancer Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. | Front Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β-catenin signaling and tumor growth. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. | Elife | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. | Sci Rep | 2021 | Its Methods give the RRID and name the line | PubMed | |
| A Pharmacogenomic Landscape in Human Liver Cancers. | Cancer Cell | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. | Gastroenterology | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0497/papers